HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N-(2-adamantyl)-N-p-bromophenylamine

Also Known As:

ladasten

Networked: 14 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Adamantane: 182
        N-(2-adamantyl)-N-p-bromophenylamine: 14
    - Bridged-Ring Compounds: 1
      - Adamantane: 182
        N-(2-adamantyl)-N-p-bromophenylamine: 14

Experts

1.	Neznamov, G G: 4 articles (01/2012 - 07/2008)
2.	Siuniakov, S A: 4 articles (01/2012 - 07/2008)
3.	Reutova, M A: 3 articles (01/2012 - 01/2009)
4.	Seredenin, S B: 3 articles (11/2011 - 05/2009)
5.	Bochkarev, V K: 2 articles (01/2012 - 07/2008)
6.	Durnev, A D: 2 articles (11/2011 - 01/2011)
7.	Kovalenko, L P: 2 articles (11/2011 - 01/2011)
8.	Tallerova, A V: 2 articles (11/2011 - 01/2011)
9.	Dorofeeva, O A: 2 articles (01/2011 - 01/2009)
10.	Siuniakov, T S: 2 articles (01/2011 - 01/2009)

Related Diseases

1.	Neurasthenia 01/01/2009 - "An aim of a randomized blind study was to assess therapeutic efficacy and safety of ladasten used as an antiastenic drug in patients with neurasthenia. " 01/01/2012 - "The study was focused on the clinico-pharmacological analysis of differences between subjective and objective assessment of the effects of antiasthenic drug ladasten and placebo effects in patients with neurasthenia with different individual patterns manifested in their EEG alpha rhythms and MMPI findings. " 01/01/2012 - "It is established that, in patients with neurasthenia characterized by reduced EEG alpha activity combined with emotional lability and inertness, the therapeutic action and effectiveness of ladasten and placebo was more robust (the subjective estimation was higher) than in patients with prominent alpha rhythm and sthenic personal traits. " 01/01/2012 - "[Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types]." 01/01/2011 - "Self-evaluation of the effect of single-dose (15 mg) ladasten administration versus placebo has been studied in patients with neurasthenia diagnosis. "
2.	Neoplasms (Cancer) 01/01/2015 - "It is showed that the use of 100 mg of ladasten, 16 mg of ondansetron orally per day and 50 mg of agomelatine per night is more effective in therapy for fatigue/weakness syndrome in incurable cancer patients compared to standard therapy."
3.	Fatigue 01/01/2015 - "It is showed that the use of 100 mg of ladasten, 16 mg of ondansetron orally per day and 50 mg of agomelatine per night is more effective in therapy for fatigue/weakness syndrome in incurable cancer patients compared to standard therapy."
4.	Sleep Wake Disorders 01/01/2010 - "We determined clinical efficacy of ladasten in regard to anxiety-depressive spectrum disorders, autonomic dystonia, sleep disorders. " 01/01/2010 - "We determined clinical efficacy of ladasten in regard to anxiety-depressive spectrum disorders, autonomic dystonia, sleep disorders. "
5.	Dystonia (Limb Dystonia) 01/01/2010 - "We determined clinical efficacy of ladasten in regard to anxiety-depressive spectrum disorders, autonomic dystonia, sleep disorders. " 01/01/2010 - "We determined clinical efficacy of ladasten in regard to anxiety-depressive spectrum disorders, autonomic dystonia, sleep disorders. "

Related Drugs and Biologics

1.	Ondansetron (Zofran)
2.	agomelatine (S20098)
3.	Cytokines
4.	Anti-Anxiety Agents (Anxiolytics)

Related Therapies and Procedures

1.	Therapeutics